1. What Is the Role of Injectables in the Modern Era of MS Treatment?

3. The "Platform Injectables"

4. IFNβ-1b: 11-Year Follow-Up of BENEFIT Trial in CIS

5. IM IFNβ-1a 15-Year Follow-Up: Mean EDSS

6. Long-Term Results With GA: 15-Year Open-Label Study

7. UK Multiple Sclerosis Risk-Sharing Scheme: 6 Years of Injectables

8. Injectables: Long-Term Safety

9. Strategies for Minimizing Injection-Site Reactions

10. ADVANCE: SC PegIFNβ-1a

11. GALA 3-Year Results: Efficacy of GA 40 mg/mL 3X Weekly

12. SC PegIFNβ-1a and GA 40 mg/mL 3X Weekly: Safety

13. Adherence With New Formulations of SC IFNβ-1a and GA

14. Using Injectables in Clinical Practice: Considerations

15. Importance of Injectables in the Treatment Armamentarium

16. Role of Platform Injectables: Lessons From Hypertension Management

17. Clinical Trials With Injectables: Applying Data to Today's MS Patients

18. Sequencing With Platform Injectables

19. CombiRx: IM IFNβ-1a Plus GA

20. SENTINEL: IM IFNβ-1a Plus Natalizumab

21. Combining Immunomodulators: Lessons From Rheumatoid Arthritis Management

22. Challenges in Developing Follow-On Products

23. IFNβ Plus Teriflunomide

24. TV-5010 Development: Short-Term Preclinical and Clinical Studies Did Not Raise Concerns

25. TV-5010 Development: Long-term Toxicology Studies Raised Concerns

26. Meeting the Challenges in Developing Follow-On Products: Regulatory Guidance

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)